Fluoguide AS
STO:FLUO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.9
75.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fluoguide AS
Total Liabilities & Equity
Fluoguide AS
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluoguide AS
STO:FLUO
|
Total Liabilities & Equity
kr29.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
230%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Total Liabilities & Equity
kr38.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
34%
|
CAGR 10-Years
30%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Liabilities & Equity
kr9.6B
|
CAGR 3-Years
80%
|
CAGR 5-Years
41%
|
CAGR 10-Years
39%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Liabilities & Equity
€1.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
53%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Liabilities & Equity
kr14.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
40%
|
CAGR 10-Years
28%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Liabilities & Equity
kr131.5m
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Total Liabilities & Equity?
Total Liabilities & Equity
29.6m
DKK
Based on the financial report for Dec 31, 2023, Fluoguide AS's Total Liabilities & Equity amounts to 29.6m DKK.
What is Fluoguide AS's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
230%
Over the last year, the Total Liabilities & Equity growth was -17%. The average annual Total Liabilities & Equity growth rates for Fluoguide AS have been 21% over the past three years , 230% over the past five years .
You don't have any saved screeners yet
